LY3214996
Showing 1 - 11 of 11
Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)
Recruiting
- Cancer
- +6 more
- Abemaciclib
- LY3214996
-
Indianapolis, IndianaIndiana University Hospital / IU Simon Cancer Center
Jan 12, 2023
Acute Myeloid Leukemia Trial in Boston (LY3214996)
Recruiting
- Acute Myeloid Leukemia
- LY3214996
-
Boston, MassachusettsDana Farber Cancer Institute
Jun 6, 2022
Pancreatic Cancer, Advanced Cancer Trial in Boston, Chapel Hill (Hydroxychloroquine Sulfate, LY3214996)
Recruiting
- Pancreatic Cancer
- Advanced Cancer
- Hydroxychloroquine Sulfate
- LY3214996
-
Boston, Massachusetts
- +2 more
Apr 6, 2022
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston
Recruiting
- Metastatic Colon Adenocarcinoma
- +30 more
- Abemaciclib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2022
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal
Recruiting
- Borderline Resectable Pancreatic Adenocarcinoma
- +11 more
- Cobimetinib
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Mar 22, 2022
Advanced Cancer, Metastatic Melanoma, Metastatic NSCLC Trial in Worldwide (LY3214996, Midazolam, Abemaciclib)
Active, not recruiting
- Advanced Cancer
- +3 more
- LY3214996
- +6 more
-
Washington, District of Columbia
- +12 more
Sep 2, 2021
NSCLC, Colorectal Neoplams, Endometrial Tumors Trial in Worldwide (LY3537982, Abemaciclib, Erlotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +4 more
- LY3537982
- +7 more
-
Los Angeles, California
- +21 more
Jul 22, 2022
Healthy Trial in Madison (LY3214996, [14C]-LY3214996)
Completed
- Healthy
- LY3214996
- [14C]-LY3214996
-
Madison, WisconsinCovance Clinical Research Inc
Oct 26, 2019
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma Trial (Ibrutinib, LY3214996)
Withdrawn
- Chronic Lymphocytic Leukemia
- +3 more
- Ibrutinib
- LY3214996
- (no location specified)
Feb 3, 2020